BEGIN:VCALENDAR PRODID:-//Microsoft Corporation//Outlook 16.0 MIMEDIR//EN VERSION:2.0 METHOD:REQUEST X-MS-OLK-FORCEINSPECTOROPEN:TRUE BEGIN:VTIMEZONE TZID:W. Europe Standard Time BEGIN:STANDARD DTSTART:16011028T030000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=10 TZOFFSETFROM:+0200 TZOFFSETTO:+0100 END:STANDARD BEGIN:DAYLIGHT DTSTART:16010325T020000 RRULE:FREQ=YEARLY;BYDAY=-1SU;BYMONTH=3 TZOFFSETFROM:+0100 TZOFFSETTO:+0200 END:DAYLIGHT END:VTIMEZONE BEGIN:VEVENT ATTENDEE;CN="Stierli, Peter";RSVP=TRUE:mailto:Peter.Stierli@siegfried.ch ATTENDEE;CN="Neukamm, Olivia";RSVP=TRUE:mailto:Olivia.Neukamm@siegfried.ch ATTENDEE;CN="Lehman, Madison";RSVP=TRUE:mailto:Madison.Lehman@siegfried.ch CLASS:PUBLIC CREATED:20250829T082849Z DESCRIPTION:Faster by design: What’s driving the acceleration of drug dev elopment timelines?\n\nAccelerated timelines are no longer the exception —they’re becoming the norm across the pharma industry. An increasing n umber of molecules are receiving conditional or expedited approvals\, ofte n at earlier stages of development. This trend is reshaping expectations n ot only for clinical progress but also for CMC\, where development windows are tightening significantly. Nearly two-thirds of recent FDA novel drug approvals occurred under an accelerated pathway. In this panel discussion\ , industry leaders will explore the forces driving this shift.\n\n \n\nSpe akers: \n\n* Stefan Randl\, Chief Scientific Officer at Siegfried\n* Raman Sehgal Sehgal\, Host at Molecule to Market\n* Shilpi Ghosh\, CDMO Site Ma nagement Commercial Chapter Lead and Localization at Roche\n* Carina Syrin g\, Vice President\, Head of External Manufacturing at Bristol Myers Squib b\n* Arantxa Sancho\, Director of the Medical & Scientific Department at f armaindustria\n\n DTEND;TZID="W. Europe Standard Time":20251029T162500 DTSTAMP:20250829T080740Z DTSTART;TZID="W. Europe Standard Time":20251029T154500 LAST-MODIFIED:20250829T082849Z LOCATION:CPHI Future of Pharma & Ingredients Theatre: Hall 12.1 - 12.1C68 ORGANIZER;CN="Siegfried Communications":mailto:communications@siegfried.ch PRIORITY:5 SEQUENCE:2 SUMMARY;LANGUAGE=de-ch:Faster by design: What’s driving the acceleration of drug development timelines? TRANSP:OPAQUE UID:040000008200E00074C5B7101A82E0080000000030504A02C918DC01000000000000000 01000000027CC58CAB8903748AE7B268E53C82510 X-ALT-DESC;FMTTYPE=text/html: